Increasingly efficient serological tests thanks to a new ECL based mechanism

June 05, 2020

A research group led by the University of Bologna identified a new mechanism that allows to obtain serological tests that are quicker, more cost-effective and more reliable than those currently in use. This mechanism is based on the technique of electrochemiluminescence (ECL) and is applicable to serological tests devised to detect the antibodies against SARS-CoV-2. The future of this innovative technique is an industrial application, as two leading firms in the fields of diagnostics and technologies, were also involved in this research: the Germany-based Roche Diagnostic and the Japanese Hitachi High Tech.

The study was published on Nature Communications and its outcomes show serological tests with increased sensitivity levels up to 128% more than those currently in use is possible thanks to highly efficient reactants.

"The results we obtained mark a new milestone in the state of the art of signal enhancement of ECL-based immunoassays", says Francesco Paolucci leader of the research group and professor at the University of Bologna. "This milestone is the outcome of years and years of international research into electrochemistry and of a close synergy with R&D sectors".

Serological tests are based on the ability to translate into measurable and visible signals the interactions between some molecules and the antibodies the test intends to quantify. ECL can play a major role here, as it relies on an electrochemical reaction producing a light signal. In the case of serological tests, electrochemiluminescence "switches on" the antibodies as if they were lamps.

This mechanism has, however, some limitations: the molecules that are able to prompt this reaction are in very low concentrations in the human blood. Therefore, we need highly-sensitive techniques to identify the antibodies in the blood. The results obtained by this research group seems to go exactly in this direction.

"Our work represents something unprecedented in the field of ECL because it relies on the enhancement of the signal as opposed to the enhancement of the target as it usually happens with enzymatic methods or PCR (Polymerase Chain Reaction)", explains Giovanni Valenti, study coordinator and researcher at the University of Bologna. "These results pave the way for the development of ultra-sensitive serological tests".

The researchers obtained a twofold result with this study. On the one hand, they refined the mechanisms regulating ECL analyses; on the other hand, they employed these mechanisms to develop new reactants that allow to obtain far more efficient serological tests.

"From these results, we managed to identify highly efficient reactants that are able to enhance the sensitivity of this technique way beyond that currently employed for serological tests", confirms Alessandra Zanut, first author of the study and researcher at the University of Bologna. "With this technique, we obtained an ECL signal enhancement up to 128% compared to current techniques".
The title of this study is "Insights into the mechanism of coreactant electrochemiluminescence facilitating enhanced bioanalytical performance" and was published on Nature Communications. It was carried out by a research group at the Chemistry Department "Giacomo Ciamician" of the University of Bologna.

The research coordinators are Francesco Paolucci and Giovanni Valenti, in collaboration with Fabrizia Negri. Alessandra Zanut, Andrea Fiorani, Sofia Canola, Stefania Rapino, Sara Rebeccari and Massimo Marcaccio also participated in this research. Finally, this study saw the collaboration of researchers at the University of Padua as well as at Roche Diagnostic and Hitachi High Tech.

Università di Bologna

Related Antibodies Articles from Brightsurf:

Scientist develops new way to test for COVID-19 antibodies
New research details how a cell-free test rapidly detects COVID-19 neutralizing antibodies and could aid in vaccine testing and drug discovery efforts.

Mussels connect antibodies to treat cancer
POSTECH research team develops innovative local anticancer immunotherapy technology using mussel protein.

For an effective COVID vaccine, look beyond antibodies to T-cells
Most vaccine developers are aiming solely for a robust antibody response against the SARS-CoV-2 virus, despite evidence that antibodies are not the body's primary protective response to infection by coronaviruses, says Marc Hellerstein of UC Berkeley.

Children can have COVID-19 antibodies and virus in their system simultaneously
With many questions remaining around how children spread COVID-19, Children's National Hospital researchers set out to improve the understanding of how long it takes pediatric patients with the virus to clear it from their systems, and at what point they start to make antibodies that work against the coronavirus.

The behavior of therapeutic antibodies in immunotherapy
Since the late 1990s, immunotherapy has been the frontline treatment against lymphomas where synthetic antibodies are used to stop the proliferation of cancerous white blood cells.

Re-engineering antibodies for COVID-19
Catholic University of America researcher uses 'in silico' analysis to fast-track passive immunity

Seroprevalence of antibodies to SARS-CoV-2 in 10 US sites
This study estimates how common SARS-CoV-2 antibodies are in convenience samples from 10 geographic sites in the United States.

Neutralizing antibodies in the battle against COVID-19
An important line of defense against SARS-CoV-2 is the formation of neutralizing antibodies.

Three new studies identify neutralizing antibodies against SARS-CoV-2
A trio of papers describes several newly discovered human antibodies that target the SARS-CoV-2 virus, isolated from survivors of SARS-CoV-2 and SARS-CoV infection.

More effective human antibodies possible with chicken cells
Antibodies for potential use as medicines can be made rapidly in chicken cells grown in laboratories.

Read More: Antibodies News and Antibodies Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to